Core B: Biospecimen Core

项目总结 胰管疾病患者临床标本的可控性采集与处理 腺癌(PDAC)是一项有效和全面的翻译计划的关键活动 在孢子赠款的背景下进行研究。因此，Biosecimen核心(核心B)具有一个突出部分 目的：我们将收集、储存、加工和分发所有诊断为PDAC的患者的生物标本。 在该机构看到的促进基于生物显微镜的翻译研究：我们将收集恶性细胞 来自肿瘤的人群(来自手术前和手术活检)。我们还将收集正常的胰腺， 胰腺恶性病变和PDAC患者的外周血。将收集血清和血浆 以备相关及未来研究之用。将在每个患者的整个病程中收集样本(初始 介绍、前处理、后处理/后续行动)，并酌情从 以前的活组织检查/等将被取回。特别注意样本采购(例如，快速处理 组织以保存记录档案)和质量控制将被实行。样本将被加工成 每项研究所需的细胞RNA、基因组DNA、全基因组扩增DNA和蛋白质提取物。 细胞群体也将被可见地冷冻或立即处理，以用于患者来源的异种移植和/或 细胞系派生化/创建。将从这些肿瘤构建组织微阵列(TMA)，创建 为今后的研究提供了重要资源。重要的是，我们将确保所有用于研究的标本 广泛和准确地使用临床(治疗前、治疗和随访)数据进行注释 我们机构的生物信息学基础设施。来自专门的胃肠道病理学家的专家病理审查将 确保高质量的注释。这一核心的目标将通过扩大油井的范围来实现- 建立了癌症中心肿瘤库和一个正在进行的、资助的收集固体胃肠道的努力 在我们的机构里有恶性肿瘤。具体来说，Core B将扩大PDAC患者的数量 将收集生物标本，并作为一个渠道(通过数据和标本共享)，允许 PDAC恶性肿瘤的更广泛的转译研究，使用新的和以前的库 生物群落。

PROJECT SUMMARY The controlled collection and processing of clinical specimens from patients with pancreatic ductal adenocarcinoma (PDAC) is a critical activity for an efficient and comprehensive program in translational research in the context of a SPORE grant. Accordingly, the Biospecimen Core (Core B) has one overarching aim: We will collect, store, process, and distribute biospecimens from all patients with a diagnosis of PDAC seen at this institution to facilitate biospecimen-based translational research: We will collect malignant cell populations from tumors (from pre-surgical and surgical biopsies). We will also collect normal pancreas, pre- malignant pancreatic lesions, and peripheral blood from PDAC patients. Serum and plasma will be collected for correlative and future studies. Specimens will be collected throughout each patient's disease course (initial presentation, pre-treatment, post-treatment/follow-up), and, where appropriate, archival specimens from previous biopsies/etc. will be retrieved. Particular attention to specimen procurement (e.g. rapid processing of tissue to preserve transcript profiles) and quality control will be practiced. Specimens will be processed to cellular RNA, genomic DNA, whole genome amplified DNA, and protein extracts as required for each study. Cellular populations will also be viably frozen or immediately processed for patient-derived xenograft and/or cell line derivitization/creation. A tissue microarray (TMA) will be constructed from these tumors, creating an important resource for future studies. Importantly, we will ensure that all specimens used for research are extensively and accurately annotated with clinical (pre-treatment, treatment, and follow-up) data utilizing the bioinformatics infrastructure at our institution. Expert pathologic review from a dedicated GI pathologist will ensure high-quality annotation. The aims of this Core will be accomplished by expanding the scope of a well- established Cancer Center Tumor Bank and an on-going, funded effort to collect solid gastrointestinal malignancies at our institution. Specifically, Core B will expand the number of PDAC patients from whom biospecimens will be collected, and serve as a conduit (through data and specimen sharing) to allow for a broader variety of translational research studies in PDAC malignancies, using new and previously banked biospecimens.